01:25 PM EST, 03/07/2024 (MT Newswires) -- Marinus Pharmaceuticals' ( MRNS ) Ztalmy was approved by the UK Medicines and Healthcare products Regulatory Agency on Thursday for the treatment of seizures in patients with cyclin-dependent kinase-like 5 deficiency disorder.

Ztalmy, or ganaxolone, is the first anti-seizure medication approved for the treatment of this rare genetic disorder in the UK, according to MHRA.

The market authorization is based on results from a phase 3 study that showed a statistically significant reduction in seizure frequency in the drug group, compared with placebo.

The company shares were down 2.7% in recent trading.

Price: 8.79, Change: -0.24, Percent Change: -2.66